Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

作者： V H J van der Velden , A van der Sluijs-Geling , B E S Gibson , J G te Marvelde , P G Hoogeveen

DOI: 10.1038/LEU.2010.153

关键词:

摘要: Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected 94% patients. after the first course chemotherapy predicted outcome: 3-year relapse-free survival was 85%+/-8% (s.e.) MRD-negative patients (MRD or=0.5%; P<0.001), whereas overall 95%+/-5%, 70%+/-10% 40%+/-13%, respectively, (P<0.001). Multivariate analysis allowing age, karyotype, FLT3-internal tandem duplications white blood cell count at diagnosis showed that an independent prognostic factor. Although comparison paired diagnosis-relapse samples (n=23) immunophenotypic shifts 91% cases, this did not hamper analysis. In conclusion, detection is possible AML. The level provides information used to guide therapy.

参考文章(31)

J.F. San Miguel, A. Martı́nez, A. Macedo, M.B. Vidriales, C. López-Berges, M. González, D. Caballero, M.A. Garcı́a-Marcos, F. Ramos, J. Fernández-Calvo, M.J. Calmuntia, J. Diaz-Mediavilla, A. Orfao, Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood. ,vol. 90, pp. 2465- 2470 ,(1997) , 10.1182/BLOOD.V90.6.2465

JJM van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, G Saglio, E Gottardi, A Rambaldi, G Dotti, F Griesinger, A Parreira, P Gameiro, M González Diáz, M Malec, AW Langerak, JF San Miguel, A Biondi, Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. ,vol. 13, pp. 1901- 1928 ,(1999) , 10.1038/SJ.LEU.2401592

C.E. Pedreira, E.S. Costa, J. Almeida, C. Fernandez, S. Quijano, J. Flores, S. Barrena, Q. Lecrevisse, J.J.M. Van Dongen, A. Orfao, , A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders† Cytometry Part A. ,vol. 73, pp. 1141- 1150 ,(2008) , 10.1002/CYTO.A.20638

Nick Goulden, Paul Virgo, David Grimwade, Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now British Journal of Haematology. ,vol. 134, pp. 273- 282 ,(2006) , 10.1111/J.1365-2141.2006.06182.X

VHJ van der Velden, DCH Jacobs, AJM Wijkhuijs, WM Comans-Bitter, MJ Willemse, K Hählen, WA Kamps, ER van Wering, JJM van Dongen, Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL Leukemia. ,vol. 16, pp. 1432- 1436 ,(2002) , 10.1038/SJ.LEU.2402636

N Feller, M A van der Pol, A van Stijn, G W D Weijers, A H Westra, B W Evertse, G J Ossenkoppele, G J Schuurhuis, MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia Leukemia. ,vol. 18, pp. 1380- 1390 ,(2004) , 10.1038/SJ.LEU.2403405

N Boeckx, MJ Willemse, T Szczepanski, VHJ van der Velden, AW Langerak, P Vandekerckhove, JJM van Dongen, Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia. ,vol. 16, pp. 368- 375 ,(2002) , 10.1038/SJ.LEU.2402387

Anna van Rhenen, Guus A. M. S. van Dongen, Angèle Kelder, Elwin J. Rombouts, Nicole Feller, Bijan Moshaver, Marijke Stigter-van Walsum, Sonja Zweegman, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Blood. ,vol. 110, pp. 2659- 2666 ,(2005) , 10.1182/BLOOD-2007-03-083048

E.G. van Lochem, V.H.J. van der Velden, H.K. Wind, J.G. te Marvelde, N.A.C. Westerdaal, J.J.M. van Dongen, Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts Cytometry Part B-clinical Cytometry. ,vol. 60, pp. 1- 13 ,(2004) , 10.1002/CYTO.B.20008

10.

Adriano Venditti, Anna Tamburini, Francesco Buccisano, Giovanni Del Poeta, Luca Maurillo, Paola Panetta, Kathleen Alessandra Scornajenghi, Christina Cox, Sergio Amadori, Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. Journal of Hematotherapy & Stem Cell Research. ,vol. 11, pp. 349- 357 ,(2002) , 10.1089/152581602753658538

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

来源期刊

我的账户

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

来源期刊

相似文章 10

我的账户